Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Evaluation Of GROC (Gemcitabine- Rituximab-Oxaliplatin Combination) Given Every 14 Days For The Treatment Of Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma

NCT01538641 is registered in ClinicalTrials.gov with Auxilio Mutuo Cancer Center as lead sponsor.

NCT NCT01538641
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01538641 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Evaluation Of GROC (Gemcitabine- Rituximab-Oxaliplatin Combination) Given Every 14 Days For The Treatment Of Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma
Lead sponsor
Auxilio Mutuo Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2003
Completion date
December 31, 2008
Enrollment
43 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

refractory aggressive non-hodgkin's lymphoma, relapsing aggressive non-hodgkin's lymphoma